Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1997 7
1998 23
1999 59
2000 121
2001 172
2002 321
2003 393
2004 489
2005 624
2006 809
2007 986
2008 1185
2009 1316
2010 1473
2011 1619
2012 1779
2013 1859
2014 2048
2015 2101
2016 2049
2017 2153
2018 2111
2019 2131
2020 2364
2021 492
Text availability
Article attribute
Article type
Publication date

Search Results

25,199 results
Results by year
Filters applied: . Clear all
Page 1
A tale of two antibodies: obinutuzumab versus rituximab.
Freeman CL, Sehn LH. Freeman CL, et al. Br J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9. Br J Haematol. 2018. PMID: 29741753 Review.
While rituximab has dramatically improved outcomes for patients with CD20(+) malignancies for two decades, responses are not universal and resistance can develop. ...The benefit conferred by obinutuzumab over rituximab may be context-specific and vary based on histo …
While rituximab has dramatically improved outcomes for patients with CD20(+) malignancies for two decades, responses are not universa …
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Salles G, et al. Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5. Adv Ther. 2017. PMID: 28983798 Free PMC article. Review.
For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. ...Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the t …
For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but als …
Rituximab biosimilars for lymphoma in Europe.
Jurczak W, Długosz Danecka M, Buske C. Jurczak W, et al. Expert Opin Biol Ther. 2019 Oct;19(10):1045-1056. doi: 10.1080/14712598.2019.1665017. Expert Opin Biol Ther. 2019. PMID: 31512535 Review.
Approved rituximab biosimilars have been comprehensively demonstrated to match the reference medicine. ...Focusing on biosimilars of rituximab, we examine in detail the evidence for biosimilarity for the two rituximab biosimilars that are approved in Europe a …
Approved rituximab biosimilars have been comprehensively demonstrated to match the reference medicine. ...Focusing on biosimilars of …
Rituximab treatment for multiple sclerosis.
Ineichen BV, Moridi T, Granberg T, Piehl F. Ineichen BV, et al. Mult Scler. 2020 Feb;26(2):137-152. doi: 10.1177/1352458519858604. Epub 2019 Jun 25. Mult Scler. 2020. PMID: 31237800
Rituximab, a chimeric anti-CD20-antibody, attracts increasing attention as a treatment option for multiple sclerosis (MS). Apart from smaller controlled trials, an increasing number of studies in real-world populations indicate high efficacy based on clinical and neuroradi
Rituximab, a chimeric anti-CD20-antibody, attracts increasing attention as a treatment option for multiple sclerosis (MS). Apart from
Rituximab in ANCA-Associated Vasculitis.
Hassan RI, Gaffo AL. Hassan RI, et al. Curr Rheumatol Rep. 2017 Feb;19(2):6. doi: 10.1007/s11926-017-0632-1. Curr Rheumatol Rep. 2017. PMID: 28155022 Review.
PURPOSE OF REVIEW: The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). ...RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; i …
PURPOSE OF REVIEW: The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and …
Rituximab in systemic autoimmune rheumatic diseases: indications and practical use.
Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Berghen N, et al. Acta Clin Belg. 2019 Aug;74(4):272-279. doi: 10.1080/17843286.2018.1521904. Epub 2018 Sep 26. Acta Clin Belg. 2019. PMID: 30253707 Review.
Several guidelines have adopted these indications. In addition, there is a consensus about the use of rituximab in refractory myositis. The role of rituximab in interstitial lung disease associated with these SARDs needs to be further explored. Conclusion: Rituxi
Several guidelines have adopted these indications. In addition, there is a consensus about the use of rituximab in refractory myositi …
Rituximab in neurological disease: principles, evidence and practice.
Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A. Whittam DH, et al. Pract Neurol. 2019 Feb;19(1):5-20. doi: 10.1136/practneurol-2018-001899. Epub 2018 Nov 29. Pract Neurol. 2019. PMID: 30498056 Review.
Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in neurological disorders and there are no treatment guidelines. ...We provide an administration guide, checklist and patient information leaflet, which can be adapted for local use.
Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in neurological disorders and there are no
Rituximab treatment of ANCA-associated vasculitis.
Raffray L, Guillevin L. Raffray L, et al. Expert Opin Biol Ther. 2020 Aug;20(8):899-910. doi: 10.1080/14712598.2020.1748597. Epub 2020 May 5. Expert Opin Biol Ther. 2020. PMID: 32293192 Review.
INTRODUCTION: Rituximab, an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). ...Cyclophosphamide indications are likely to be restricted in the future. Whenever po …
INTRODUCTION: Rituximab, an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cytopl …
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
Damato V, Evoli A, Iorio R. Damato V, et al. JAMA Neurol. 2016 Nov 1;73(11):1342-1348. doi: 10.1001/jamaneurol.2016.1637. JAMA Neurol. 2016. PMID: 27668357 Review.
OBJECTIVE: To perform a systematic review and a meta-analysis of the efficacy and safety of rituximab use in NMOSDs, considering the potential predictive factors related to patient response to rituximab in this disease. ...However, the safety profile suggests cautio …
OBJECTIVE: To perform a systematic review and a meta-analysis of the efficacy and safety of rituximab use in NMOSDs, considering the …
[Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. Midaglia L, et al. Rev Neurol. 2018 Jan 1;66(1):25-32. Rev Neurol. 2018. PMID: 29251340 Free article. Review. Spanish.
AIM: To address the main aspects of efficacy, effectiveness and safety of rituximab in the treatment of MS. DEVELOPMENT: PubMed review of placebo-controlled clinical trials, prospective open label studies, retrospective observational studies, and case series using ritux
AIM: To address the main aspects of efficacy, effectiveness and safety of rituximab in the treatment of MS. DEVELOPMENT: PubMed revie …
25,199 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page